Neridronic acid
(Redirected from Neridronate)
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.163.818 |
| Chemical and physical data | |
| Formula | C6H17NO7P2 |
| Molar mass | 277.150 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Neridronic acid (INN; the anion is called neridronate) is a bisphosphonate. In Italy it is used to treat osteogenesis imperfecta and Paget's disease of bone.[1]
A 2013 clinical trial suggests complex regional pain syndrome type 1 (CRPS) responds to treatment with intravenous neridronate.[2]
References
[edit]- ^ Gatti D, Viapiana O, Idolazzi L, Fracassi E, Adami S (2009). "Neridronic acid for the treatment of bone metabolic diseases". Expert Opin Drug Metab Toxicol. 5 (10): 1305–11. doi:10.1517/17425250903029190. PMID 19761412. S2CID 22274296.
- ^ Varenna M, Adami S, Rossini M, et al. (March 2013). "Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study". Rheumatology. 52 (3): 534–42. doi:10.1093/rheumatology/kes312. PMID 23204550.
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |